SEARCH RESULT

Total Matching Records found : 193

Indian patent rulings may face legal heat internationally -Soma Das

-The Economic Times The recent patent rulings in India may get frequently challenged in international courts if the government yields to the European Union's demand of including matters related to intellectual property in the investors-state dispute mechanism in their proposed trade pact, health activist groups have warned. An investor-state dispute resolution mechanism typically allows foreign investors to sue countries for compensation if national laws, policies, court rulings of the country infringe upon...

More »

More battles in store-Aarti Dhar

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...

More »

Patent justice-Sakthivel Selvaraj

-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

More »

SC verdict on Novartis AG plea today

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...

More »

No tax relief for SEZs, rules Chidambaram -Sidhartha

-The Times of India In a major setback to special economic zone (SEZ) developers, finance minister P Chidambaram has turned down the commerce department's plea to cut the minimum alternate tax (MAT), which was imposed two years ago. A lower or no tax burden was cited as one of the main drivers for boosting investment in what were until recently duty-free enclaves. The commerce department had made a case for reversing Chidambaram's...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close